Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently,
we started the first-in-human treatment with an α-radionuclide–labeled PSMA ligand. …

Purpose Radiopeptide therapy using a somatostatin analogue labelled with a beta emitter
such as 90 Y/ 177 Lu-DOTATOC is a new therapeutic option in neuroendocrine cancer. …

The aim of this study was to develop a treatment protocol for 225 Ac-PSMA-617 α-radiation
therapy in advanced-stage, metastatic castration-resistant prostate cancer patients with …

Background: Recent reports of the remarkable therapeutic efficacy of 225Ac-labeled PSMA-
617 for therapy of metastatic castration-resistant prostate cancer have underlined the clinical …

This work describes a method for the separation and purification of Ac-225 from a Th-229
source. The procedure is based on the combination of ion exchange and extraction …

Results: Radiolabelingefficiencyof the CHX-A-DTPA-HuM195 construct with 213Biwas 78%
±10%(n= 46) after 10 min at specific activities of up to 1110MBq/mg. The immunoreactivity …

The feasibility of producing Ac-225 by proton irradiation of Ra-226 in a cyclotron through the
reaction Ra-226(p,2n)Ac-225 has been experimentally demonstrated for the first time. …

α-Particles are suitable to treat cancer micrometastases because of their short range and
very high linear energy transfer. α-Particle emitter 213 Bi-based radioimmunotherapy has …

Purpose: Malignant glial brain tumors consistently overexpress neurokinin type 1 receptors.
In classic seed-based brachytherapy, one to several rigid 125 I seeds are inserted, mainly …

Molecular nanomagnets that display magnetic bistability are the subject of intensive investigation
due to their unique potential in ultrahigh-density memory components and spintronic …